Abstract
BackgroundDespite numerous therapeutic options, safe and curative therapy is unavailable for most patients with chronic lymphocytic leukemia (CLL). A drawback of current therapies such as the anti-CD20 monoclonal antibody (mAb)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have